We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Authors
Tsushima, Takafumi; Sato, Nobue; Guo, Yong-Mei; Uchiyama, Satoshi; Nakamura, Hirotaka; Nagata, Akihito; Song-Gi, Chi; Yamauchi, Nobuhiko; Minami, Yosuke; Yuda, Junichiro
- Abstract
In the GIMEMA LAL1811 trial, including "unfit" patients with newly diagnosed Ph + ALL, 44 patients received 45 mg of ponatinib (PONA) daily with prednisone, and complete hematological remission (CHR) was achieved in 86.4% at 24 weeks. The combination of BCR-ABL tyrosine kinase inhibitors (TKIs) and chemotherapy has significantly improved outcomes among patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia (ALL) [[1]].
- Subjects
FRAIL elderly; LYMPHOBLASTIC leukemia; OLDER patients; ACUTE leukemia; TUMOR lysis syndrome; FEBRILE neutropenia
- Publication
Annals of Hematology, 2022, Vol 101, Issue 7, p1603
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-022-04796-w